Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

BACKGROUND: Long-acting injectable cabotegravir (CAB LA) is a novel integrase inhibitor in advanced clinical development for HIV treatment and HIV prevention. We investigated the terminal pharmacokinetics and safety of CAB LA after final injection as part of a Phase 2 study. METHODS: We performed a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet HIV
Päätekijät: Landovitz, Raphael J., Li, Sue, Eron, Joseph J., Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Magnus, Manya, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A., Eshleman, Susan H., Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R., Margolis, David, Cohen, Myron S., McCauley, Marybeth, Hendrix, Craig W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7859863/
https://ncbi.nlm.nih.gov/pubmed/32497491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(20)30106-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia